Literature DB >> 28206944

Improved Postoperative Survival for Intraductal-Growth Subtype of Intrahepatic Cholangiocarcinoma.

Laura L Dover1, Rojymon Jacob, Thomas N Wang, Joseph H Richardson, David T Redden, Peng Li, Derek A DuBay.   

Abstract

Intrahepatic cholangiocarcinoma (ICC) is classified according to the following subtypes: massforming (MF), periductal infiltrating (PI), and intraductal growth (IG). The aim of this study is to measure the association between ICC subtypes and patient survival after surgical resection. Data were abstracted on all patients treated with definitive resections of ICC at a single institution between 2000 and 2011 with at least three years follow-up. Survival estimates were quantified using Kaplan-Meier curves and compared using the log-rank test. There were 37 patients with ICC treated with definitive partial hepatectomies with a median survival of 33.5 months. Tumor stage (P < 0.0001), satellitosis (P < 0.001), lymphovascular space invasion (P = 0.003), and macroscopic subtype (P = 0.003) were predictive of postoperative survival. Disease-free survivals for MF, PI, and IG subtypes, respectively, were 30 per cent, 0 per cent, and 57 per cent (P = 0.017). Overall survivals among ICC macroscopic subtypes were as follows: MF 37 per cent, PI 0 per cent, and IG 71 per cent (P = 0.003). Although limited by the small sample size of this rare cancer, this study demonstrates significant differences among macroscopic subtypes of ICC in both disease-free survivals and overall survivals after definitive partial hepatectomy.

Entities:  

Mesh:

Year:  2016        PMID: 28206944      PMCID: PMC5748294     

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  34 in total

1.  Surgical treatment of intrahepatic cholangiocarcinoma: four patients surviving more than five years.

Authors:  J Yamamoto; T Kosuge; T Takayama; K Shimada; M Makuuchi; J Yoshida; M Sakamoto; S Hirohashi; S Yamasaki; H Hasegawa
Journal:  Surgery       Date:  1992-06       Impact factor: 3.982

2.  Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features.

Authors:  Jau-Yu Liau; Jia-Huei Tsai; Ray-Hwang Yuan; Chih-Ning Chang; Hsin-Jung Lee; Yung-Ming Jeng
Journal:  Mod Pathol       Date:  2014-01-10       Impact factor: 7.842

3.  K-ras mutation is strongly associated with perineural invasion and represents an independent prognostic factor of intrahepatic cholangiocarcinoma after hepatectomy.

Authors:  Tse-Ching Chen; Yi-Yin Jan; Ta-Sen Yeh
Journal:  Ann Surg Oncol       Date:  2012-07       Impact factor: 5.344

4.  Multicentric evaluation of a clinical and prognostic scoring system predictive of survival after resection of intrahepatic cholangiocarcinomas.

Authors:  Georgios C Sotiropoulos; Masaru Miyazaki; Manousos M Konstadoulakis; Andreas Paul; Ernesto P Molmenti; Ilias P Gomatos; Arnold Radtke; Hideo A Baba; Susanne Beckebaum; Eirini I Brokalaki; Masayuki Ohtsuka; Myron E Schwartz; Christoph E Broelsch; George Sgourakis
Journal:  Liver Int       Date:  2010-02-05       Impact factor: 5.828

Review 5.  Review to better understand the macroscopic subtypes and histogenesis of intrahepatic cholangiocarcinoma.

Authors:  Yuichi Sanada; Yujo Kawashita; Satomi Okada; Takashi Azuma; Shigetoshi Matsuo
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

6.  Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period.

Authors:  Hauke Lang; Georgios C Sotiropoulos; Nils R Frühauf; Marco Dömland; Andreas Paul; Eva-Maria Kind; Massimo Malagó; Christoph E Broelsch
Journal:  Ann Surg       Date:  2005-01       Impact factor: 12.969

7.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

8.  Clinicopathological characteristics of intrahepatic cholangiocellular carcinoma presenting intrahepatic bile duct growth.

Authors:  Yusuke Yamamoto; Kazuaki Shimada; Yoshihiro Sakamoto; Minoru Esaki; Satoshi Nara; Daisuke Ban; Tomoo Kosuge; Hidenori Ojima
Journal:  J Surg Oncol       Date:  2009-03-01       Impact factor: 3.454

9.  Intrahepatic peripheral cholangiocarcinoma: mode of spread and choice of surgical treatment.

Authors:  A Sasaki; M Aramaki; K Kawano; Y Morii; K Nakashima; T Yoshida; S Kitano
Journal:  Br J Surg       Date:  1998-09       Impact factor: 6.939

Review 10.  A review and update on cholangiocarcinoma.

Authors:  Matthew J Olnes; Rodrigo Erlich
Journal:  Oncology       Date:  2004       Impact factor: 2.935

View more
  4 in total

1.  Prognostic factors for patients with mass-forming intrahepatic cholangiocarcinoma: A case series of 68 patients.

Authors:  Jian Feng; Bin Liang; Hang-Yu Zhang; Zhe Liu; Kai Jiang; Xiang-Qian Zhao
Journal:  World J Gastrointest Surg       Date:  2022-05-27

Review 2.  Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma.

Authors:  Xing Chen; Jinpeng Du; Jiwei Huang; Yong Zeng; Kefei Yuan
Journal:  J Clin Transl Hepatol       Date:  2022-01-04

3.  Macroscopic types of intrahepatic cholangiocarcinoma and the eighth edition of AJCC/UICC TNM staging system.

Authors:  Ze-Wu Meng; Wei Pan; Hai-Jie Hong; Jiang-Zhi Chen; Yan-Ling Chen
Journal:  Oncotarget       Date:  2017-09-15

4.  Long noncoding RNA LINC01296 promotes tumor growth and progression by sponging miR-5095 in human cholangiocarcinoma.

Authors:  Dawei Zhang; Haiyan Li; Juping Xie; Decan Jiang; Liangqi Cao; Xuewei Yang; Ping Xue; Xiaofeng Jiang
Journal:  Int J Oncol       Date:  2018-04-05       Impact factor: 5.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.